FeesSafety
Pluang+

SELLAS Life Sciences raises $172.5M in public offering including full exercise of underwriters' option.

Company Fundamentals
20 Nov 2026, 23:01 WIB
GlobeNewsWire
View Source
Bullish
SELLAS Life Sciences raises $172.5M in public offering including full exercise of underwriters' option.

SELLAS Life Sciences Group, a clinical-stage biopharmaceutical company, closed an underwritten public offering of 13.27 million shares at $13 each, raising $172.5 million before expenses. The offering included full exercise of underwriters' option to buy an additional 1.73 million shares. Proceeds will support development of SELLAS' cancer therapies, including its lead candidate GPS and SLS009. The offering attracted new healthcare-focused institutional investors and was managed by J.P. Morgan, TD Cowen, and others. This funding bolsters SELLAS' pipeline as it advances treatments for various cancers.

SELLAS Life Sciences shares are trading at USD 13.82 on Pluang, down 7.00% for the day, reflecting active market adjustments following the recent public offering. The stock's market cap stands at $3.03 billion with a high volume of 36,199,583 shares traded. These figures are current as of Nov 21, 2026 04:11 WIB.

More News (SLS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App